Top

World Journal of Surgery

Published in:

01-04-2016 | Original Scientific Report

The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution

Authors: Se-Jin Baek, Hyuk Hur, Byung-Soh Min, Seung-Hyuk Baik, Kang-Young Lee, Nam-Kyu Kim

Published in: World Journal of Surgery | Issue 4/2016

Abstract

Background

Bone metastasis in patients with colorectal cancer (CRC) is very rare, and data are extremely lacking. We aimed to evaluate the characteristics of bone metastasis in patients with CRC.

Materials and methods

We performed a chart review of 63 patients (1.1 %) with bone metastasis among 5479 patients who underwent surgery for CRC.

Results

Most patients were stage 3 (17.5 %) or 4 (73.0 %), and 32 patients (50.8 %) were diagnosed with bone metastasis at initial diagnoses of CRC. Thirty-one patients developed bone metastasis during the follow-up period with median 10.1-month interval. PET–CT was most frequently used for the diagnosis of bone metastasis (71.4 %), and the spine was the most commonly involved site (77.8 %). Most patients had multiple bone metastases (73.0 %) and other metastases (87.3 %). Bone pain was the most common skeletal-related event (25.4 %), and patients were treated with radiation (25.4 %), surgery (14.3 %), or bisphosphonate (6.3 %). The median survival time was 17.8 months, and the 5-year survival rate was 5.7 %. In the multivariate analysis, the risk factors for survival included initial bone metastasis (hazard ratio [HR] 3.03; P < 0.001) and bone metastasis from colon cancer (HR 1.87; P = 0.04).

Conclusion

Bone metastasis in patients with CRC is extremely rare and shows poor prognosis.

O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425CrossRefPubMed

Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113CrossRefPubMed

Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ (2009) Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 9:274PubMedCentralCrossRefPubMed

Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254CrossRefPubMed

Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594CrossRefPubMed

Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595–603CrossRefPubMed

Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001–1010CrossRefPubMed

De Marinis F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4:1280–1288CrossRefPubMed

Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882CrossRefPubMed

10.

Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29:1146–1150PubMedCentralCrossRefPubMed

11.

Ganry O, Lapotre-Ledoux B, Fardellone P, Dubreuil A (2008) Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol 23:467–473CrossRefPubMed

12.

Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581CrossRefPubMed

13.

Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799–802PubMedCentralCrossRefPubMed

14.

Nozue M, Oshiro Y, Kurata M et al (2002) Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep 9:109–112PubMed

15.

Heras P, Karagiannis S, Kritikos K, Hatzopoulos A, Mitsibounas D (2007) Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 16:539–542CrossRef

16.

Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMed

17.

Rotolo N, De Monte L, Imperatori A, Dominioni L (2007) Pulmonary resections of single metastases from colorectal cancer. Surg Oncol 16:S141–S144CrossRefPubMed

18.

Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR (2011) Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol 2:326–328PubMedCentralCrossRefPubMed

19.

Santini D, Tampellini M, Vincenzi B et al (2012) Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 23:2072–2077CrossRefPubMed

20.

Fairchild A, Barnes E, Ghosh S et al (2009) International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 75:1501–1510CrossRefPubMed

21.

Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317–7325CrossRefPubMed

22.

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045PubMedCentralCrossRefPubMed

23.

Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405CrossRefPubMed

24.

Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312CrossRefPubMed

25.

Hattori S, Miyakawa H, Okuda K, Kudo K, Noguchi T (2004) Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases. Gan To Kagaku Ryoho 31:271–274PubMed

Title: The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution
Authors: Se-Jin Baek
Hyuk Hur
Byung-Soh Min
Seung-Hyuk Baik
Kang-Young Lee
Nam-Kyu Kim
Publication date: 01-04-2016
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 4/2016
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-015-3296-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution

Abstract

Background

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2016

Assessment of Acute Burn Management in 32 Low- and Middle-Income Countries

Hospital Utilization of Nationally Shared Liver Allografts from 2007 to 2012

High Rate of Organ/Space Surgical Site Infection After Hepatectomy with Preexisting Bilioenteric Anastomosis

Cost Effectiveness of a Fast-Track Protocol for Urgent Laparoscopic Cholecystectomies and Appendectomies

Prevalence of Inguinal Hernia in Adult Men in the Ashanti Region of Ghana

Downregulation of miR-138 as a Contributing Mechanism to Lcn-2 Overexpression in Colorectal Cancer with Liver Metastasis